UNITED GUARDIAN INC - 10-Q Summary (Q1 2009)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2009. United Guardian Inc. is a Delaware corporation engaged in the research, development, manufacturing, and marketing of cosmetic ingredients, personal care products, pharmaceuticals, and specialty industrial products. The company operates primarily from its facility in Hauppauge, New York, and is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Net Sales | $3,895,143 | $3,031,199 |
| Cost of Sales | $1,546,319 | $1,237,183 |
| Gross Margin | 60.3% | 59.2% |
| Operating Income | $1,638,839 | $1,134,704 |
| Net Income | $1,155,241 | $839,268 |
| Earnings Per Share (Basic/Diluted) | $0.23 | $0.17 |
| Cash from Operations | $1,764,429 | $1,011,137 |
| Cash and Equivalents (End of Period) | $4,050,907 | $3,768,497 |
| Total Assets | $17,559,071 | $17,283,623 (Dec 31, 2008) |
| Working Capital | $14,429,655 | $13,236,680 (Dec 31, 2008) |
| Current Ratio | 9.7 to 1 | 6.2 to 1 (Dec 31, 2008) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 28.5% ($863,944) compared to Q1 2008. This increase was driven almost entirely (over 98%) by volume increases from two specific customers.
- Product Segment Performance:
- Medical Products: Sales surged 150.0% ($599,921 increase), largely due to a primary customer stocking inventory before moving manufacturing operations to Mexico.
- Personal Care: Sales increased 17.7%, driven by a 40.0% volume increase from the largest distributor.
- Pharmaceuticals: Sales decreased 7.9% due to the timing of price increases (implemented in April 2008 vs. May 2009).
- Profitability: Operating income rose 44.4% to $1.64 million. Cost of sales as a percentage of sales improved to 39.7% from 40.8%, attributed to lower raw material costs.
- Investment Income: Decreased 28.6% to $91,602 due to lower interest rates and investment returns.
- Liquidity: Working capital increased by $1.19 million. The current ratio improved significantly to 9.7:1, primarily due to the payment of dividends payable ($1.385 million) which reduced current liabilities.
Outlook, Risks, and Management Commentary
- Guidance: Management expects pharmaceutical revenue for the full year to equal or exceed 2008 volumes. Sales to the key medical customer are expected to decline significantly for the remainder of 2009 as operations transfer to Mexico, though full-year sales to this customer are still projected to be at least 40% above 2008 levels.
- Capital Expenditures: The company does not expect to incur significant capital expenditures for the remainder of 2009.
- Pension Plan: The company is in the process of terminating its defined benefit pension plan, expecting regulatory approval in late 2009 or early 2010. Upon termination, non-vested benefits will become fully vested.
- Risks: Key risks include concentration of sales (reliance on two major customers for recent growth), potential decline in sales to the medical customer post-relocation, and general economic conditions affecting the personal care and pharmaceutical markets.
- Dividends: The company paid dividends of $1,385,003 ($0.28 per share) during the quarter.
Investor Verification Checklist
- Customer Concentration: Verify the sustainability of sales growth given that over 98% of the Q1 increase came from just two customers.
- Medical Product Volatility: Confirm the timeline and impact of the primary medical customer's manufacturing move to Mexico on future revenue streams.
- Pharmaceutical Pricing: Monitor the impact of the May 1, 2009 price increase on pharmaceutical sales volumes.
- Pension Termination: Track the regulatory approval status of the defined benefit plan termination and any associated one-time gains or costs.
- Investment Portfolio: Review the composition of marketable securities ($7.99 million) and the impact of unrealized losses ($310,974) on equity.